Pruritus pathway mediator

Pruritus pathway mediator" is not a single molecule or receptor but rather a broad term encompassing the diverse group of molecular entities that mediate the sensation and transmission of itch. These include neurotransmitters, neuropeptides, cytokines, chemokines, ion channels (such as TRP channels), histamine and its receptors (H1R and H4R), interleukins like IL‑31 and their receptors (IL‑31RA), protease activated receptors such as PAR2, extracellular matrix proteins like periostin acting via integrin αVβ3, acetylcholine acting on muscarinic M3 receptors, prostaglandins E1/E2 potentiating histaminergic itch responses, and others[1][4][6][8]. Each of these molecules may serve as an individual therapeutic target; however "pruritus pathway mediator" itself is not a canonical drug target but rather a functional category describing multiple possible targets involved in pruritic signaling. Therapeutic strategies have been developed against some key components within this group. For example: - **Histamine H1/H4 receptor antagonists** are used in allergic conditions but are often ineffective in chronic prurigo nodularis[1][4]. - **IL‑31/IL‑31RA antagonists** such as nemolizumab have shown efficacy in atopic dermatitis and prurigo nodularis[3]. - **TRPV1/TRPA1 channel antagonists** are under investigation; topical TRPV1 antagonist asivatrep has shown benefit in clinical trials[6]. - **Targeting periostin–integrin αVβ3 interaction** is being explored preclinically[4]. Because "pruritus pathway mediator" refers to an entire class of functionally related molecules rather than one defined entity with a unique structure or gene/protein product—and because it aggregates many distinct molecular targets—it should not be considered a valid canonical drug target name. Instead, structured information should be collected at the level of each specific molecule or receptor involved in pruritogenic signaling. In summary: "Pruritus pathway mediator" is too broad/vague to serve as a canonical therapeutic target; it represents an umbrella term covering numerous validated molecular targets implicated in itch pathophysiology across various diseases[8].

Other names

Pruritogensitch mediatorspruritus mediatorsitch pathway mediators